Tagged with P

Genomics Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and the added tensions this might cause with the USA.    Aside from the immediate implications for US-China strategic competition, the…

Spain According to a survey carried out by the Spanish Foundation for Science and Technology (FECYT) over half of the Spanish population believe Pseudo-therapies to be of real value.   “Public and private establishments that include pseudo-therapies will not be able to call themselves health centres,” Health Minister Maria Luisa Carcedo…

Malaysia Rashidah Ibrahim, executive director of Malaysian Vaccines & Pharmaceuticals (MVP), tells the story of MVP as the sole animal vaccines manufacturer in Malaysia. She also explains how important animal health is for human health and what plans she has set for the company moving forward.   Animal and human health…

Pharma Legal Handbook An overview of the regulation, pricing and reimbursement of drugs in Bolivia. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99.   1. What are the regulatory authorities with jurisdiction over drugs,…

Pharma Legal Handbook Preclinical and Clinical Trials in Bolivia – an overview. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99.   1. Are clinical trials required to be conducted locally as a condition (stated or…

Pharma Legal Handbook All you need to know about Marketing, Manufacturing, Packaging & Labeling, Advertising in Bolivian pharma. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99.   1. What is the authorization process for the…

Pharma Legal Handbook Bolivian regulation regarding traditional medicines and OTC products. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99   1. What are the regulatory requirements for traditional, herbal, complementary, or alternative medicines and devices?…

Pharma Legal Handbook The ins and out of product liability in Bolivian pharma. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99   1. What types of liability are recognized in your jurisdiction? Civil liability occurs…

Pharma Legal Handbook Want to know more about patents and trademarks in Bolivian pharma? Read on! Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99.   1. What are the basic requirements to obtain patent and trademark…

Pharma Legal Handbook An insight into regulatory reforms in Bolivian Pharma. Prepared in association with Indacochea & Asociados, a leading Bolivian law firm, this is an extract from The Pharma Legal Handbook: Bolivia, available to purchase here for USD 99.   1. Are there proposals for reform or significant change to the healthcare system?…

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz.   Besides the large business platform…

Opinion Martin Dewhurst, co-leader for McKinsey’s global Pharmaceuticals and Medical Products Practice, discusses the enormous potential value of digital and analytical advancements for R&D.     One of the areas with the most transformational impact is the potential to double R&D productivity over the next five to ten years.   After years of…